Skip to content

Clinical observation and research on traditional Chinese medicine prevention and treatment of epilepsy complicated with cognitive impairment based on the theory of removing stasis and eliminating phlegm

Clinical observation and research on traditional Chinese medicine prevention and treatment of epilepsy complicated with cognitive impairment based on the theory of removing stasis and eliminating phlegm

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053149
Enrollment
Unknown
Registered
2021-11-13
Start date
2021-11-30
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy with cognitive impairment

Interventions

Treatment group:Remove blood stasis and settle lampsia mixture + carbamazepine
Control group:Placebo + carbamazepine

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.The informed consent is signed; 2.Male or female aged 40 to 85 years; 3.Western clinical diagnosis conforms to the diagnostic criteria of epilepsy with cognitive impairment; MOCA [7] <26 points or MMSE [8] < 27 points; 4.Traditional Chinese medicine syndrome differentiation and stasis syndrome, phlegm syndrome, phlegm and stasis syndrome; 5.Have good compliance and informed consent; 6.Patients who meet the diagnosis.

Exclusion criteria

Exclusion criteria: 1.Breast-feeding or pregnant women; 2.Complicated with heart, brain, liver, kidney and hematopoietic system and other serious primary diseases; 3.Patients with severe intracranial infection or brain tumor; 4.Patients with serious mental diseases who cannot cooperate; patients with severe hearing loss; 5.Have recently undergone surgery or have serious injuries; 6.Patients with contraindications to the drug under study; 7.Patients who are in critical condition and find it difficult to accurately evaluate the effectiveness and safety of new drugs.

Design outcomes

Primary

MeasureTime frame
Epilepsy frequency and clinical efficacy evaluation;

Countries

China

Contacts

Public ContactYu Yangyang

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

523662182@qq.com+86 13482225915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026